Bacteriophage secondary infection

Virologica Sinica

Volumn 30, Issue 1, 2015, Pages 3-10

  Abedon, Stephen T ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

coinfection; lysis from without; lysis inhibition; parallel secondary infection; phage therapy; pharmacology; serial secondary infection; superinfection

Indexed keywords

AMBIGUITY; BACTERIOLYSIS; BACTERIOPHAGE; BIOLOGICAL THERAPY; NONHUMAN; PHAGE THERAPY; POPULATION EXPOSURE; POPULATION GROWTH; PRIMARY INFECTION; REVIEW; SECONDARY INFECTION; VIRION; ANIMAL; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIUM; COINFECTION; GENETICS; HUMAN; MICROBIOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; BACTERIA; BACTERIAL PHYSIOLOGICAL PHENOMENA; BACTERIOPHAGES; BIOLOGICAL THERAPY; COINFECTION; HUMANS;

EID: 84923184127     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-014-3547-2     Document Type: Review

References (62)

1. Abedon S. 2011. Phage therapy pharmacology: calculating phage dosing. Adv Appl Microbiol. 77:10–40.
2. Abedon S T. 1990. Selection for lysis inhibition in bacteriophage. J Theor Biol. 146:501–511.
3. Abedon S T. 1992. Lysis of lysis inhibited bacteriophage T4-infected cells. J Bacteriol. 174:8073–8080.
4. Abedon S T. 1994. Lysis and the interaction between free phages and infected cells. In: The Molecular Biology of Bacteriophage T4. Karam J D, Kutter E, Carlson K, and Guttman B (eds). Washington DC: ASM Press, pp397–405.
5. Abedon S T. 1999. Bacteriophage T4 resistance to lysis-inhibition collapse. Genet Res, 74:1–11.
6. Abedon S T. 2008. Phage population growth: constraints, games, adaptation. In: Bacteriophage Ecology. Abedon ST (ed). Cambridge: Cambridge University Press, pp64–93.
7. Abedon S T. 2009a. Bacteriophage intraspecific cooperation and defection. In: Contemporary Trends in Bacteriophage Research. Adams H T (ed). Hauppauge: Nova Science Publishers, pp191–215.
8. Abedon S T. 2009b. Disambiguating bacteriophage pseudolysogeny: an historical analysis of lysogeny, pseudolysogeny, and the phage carrier state. In: Contemporary Trends in Bacteriophage Research. Adams H T (ed). Hauppauge: Nova Science Publishers, pp285–307.
9. Abedon S T. 2009c. Kinetics of phage-mediated biocontrol of bacteria. Foodborne Pathog Dis, 6:807–815.
10. Abedon S T. 2011a. Bacteriophages and Biofilms: Ecology, Phage Therapy, Plaques. Hauppauge: Nova Science Publishers.
11. Abedon S T. 2011b. Lysis from without. Bacteriophage. 1:46–49.
12. Abedon S T. 2012a. Phage therapy best practices. In: Bacteriophages in Health and Disease. Hyman P, Abedon S T (eds). Wallingford: CABI Press, pp256–272.
13. Abedon ST. 2012b. Spatial vulnerability: bacterial arrangements, microcolonies, and biofilms as responses to low rather than high phage densities. Viruses. 4:663–687.
14. Abedon ST. 2012c. Thinking about microcolonies as phage targets. Bacteriophage. 2:200–204.
15. Abedon ST. 2014. Bacteriophages as drugs: the pharmacology of phage therapy. In: Phage Therapy: Current Research and Applications. Borysowski J, Miedzybrodzki R, and Górski A (eds). Norfolk: Caister Academic Press, pp69–100.
16. Abedon S T, Kuhl S J, Blasdel B G, Kutter E M. 2011. Phage treatment of human infections. Bacteriophage. 1:66–85.
17. Abedon S T, Thomas-Abedon C. 2010. Phage therapy pharmacology. Curr Pharm Biotechnol. 11:28–47.
18. Adams M H. 1959. Bacteriophages. New York: InterScience.
19. Barron B A, Fischetti V A, Zabriskie J B. 1970. Studies of the bacteriophage kinetics of multicellular systems: a statistical model for the estimation of burst size per cell in streptococci. J Appl Bacteriol. 33:436–442.
20. Benzer S, Hudson W, Weidel W, Delbruck M, Stent G S, Weigle J J, Dulbecco R, Watson J D, Wollman E L. 1950. A syllabus on procedures, facts, and interpretations in phage. Viruses 1950. Delbruck M (ed). Pasadena: California Institute of Technology, pp100–147.
21. Berngruber T W, Weissing F J, Gandon S. 2010. Superinfection inhibition and the evolution of viral latency. J Virol, 84:10200–10208.
22. Bigwood T, Hudson J A, Billington C. 2009. Influence of host and bacteriophage concentrations on the inactivation of foodborne pathogenic bacteria by two phages. FEMS Microbiol Lett, 291:59–64.
23. Bull J J, Regoes R R. 2006. Pharmacodynamics of non-replicating viruses, bacteriocins and lysins. Proc R Soc Lond B Biol Sci, 273:2703–2712.
24. Chan B K, Abedon S T. 2012. Phage therapy pharmacology: phage cocktails. Adv Appl Microbiol, 78:1–23.
25. Chan B K, Abedon S T, Loc-Carrillo C. 2013. Phage cocktails and the future of phage therapy. Future Microbiol, 8:769–783.
26. Davis B M, Kimsey H H, Chang W, Waldor M K. 1999. The Vibrio cholerae O139 Calcutta bacteriophage CTXϕ is infectious and encodes a novel repressor. J Bacteriol, 181:6779–6787.
27. Doermann A H. 1948. Lysis and lysis inhibition with Escherichia coli bacteriophage. J Bacteriol, 55:257–275.
28. Espeland E M, Lipp E K, Huq A, Colwell R R. 2004. Polylysogeny and prophage induction by secondary infection in Vibrio cholerae. Environ Microbiol, 6:760–763.
29. Fogg P C, Allison H E, Saunders J R, McCarthy A J. 2010. Bacteriophage lambda: a paradigm revisited. J Virol, 84:6876–6879.
30. Fogg P C M, Gossage S M, Smith D L, Saunders J R, McCarthy A J, Allison H E. 2007. Identification of multiple integration sites for Stx-phage Φ24B in the Escherichia coli genome, description of a novel integrase and evidence for a functional anti-repressor. Microbiology. 153:4098–4110.
31. + bacteriophage to progeny. J Bacteriol. 64:597–607.
32. Fukuda E, Kaminska K H, Bujnicki J M, Kobayashi I. 2008. Cell death upon epigenetic genome methylation: a novel function of methyl-specific deoxyribonucleases. Genome Biol. 9:R163.
33. Golshahi L, Seed K D, Dennis J J, Finlay W H. 2008. Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. J Aerosol Med Pulm Drug Deliv, 21:351–360.
34. Hatfull G F, Hendrix R W. 2011. Bacteriophages and their genomes. Curr Opin Virol, 1:298–303.
35. Hendrix R W. 2008. Phage evolution. In: Bacteriophage Ecology. Abedon ST (ed). Cambridge: Cambridge University Press, pp177–194.
36. Hendrix R W, Smith M C M, Burns R N, Ford M E, Hatfull G F. 1999. Evolutionary relationships among diverse bacteriophages and prophages: All the world’s a phage. Proc Natl Acad Sci USA. 96:2192–2197.
37. Hudson J A, Billington C, Carey-Smith G, Greening G. 2005. Bacteriophages as biocontrol agents in food. J Food Prot, 68:426–437.
38. Hughes K A, Sutherland I W, Jones M V. 1998. Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysac charide depolymerase. Microbiology. 144:3039–3047.
39. Hyman P, Abedon S T. 2010. Bacteriophage host range and bacterial resistance. Adv Appl Microbiol, 70:217–248.
40. Hyman P, Abedon S T. 2012. Smaller fleas: viruses of microorganisms. Scientifica. 2012:734023.
41. Iyer V N, James A P. 1978. Single-cell studies on the carrier state of bacteriophage IKe, a virus specific for conjugative plasmids of the N incompatibility and conjugative group. Can J Microbiol, 24:1595–1601.
42. Mann N H. 2003. Phages of the marine cyanobacterial picophytoplankton. FEMS Microbiol Rev, 27:17–34.
43. May R M, Anderson R M. 1983. Parasite-host coevolution. In: Coevolution. Futuyma D J, Slatkin M (eds). Sunderland: Sinauer Associates, pp186–206.
44. Moussa S H, Kuznetsov V, Tran T A, Sacchettini J C, Young R. 2012. Protein determinants of phage T4 lysis inhibition. Protein Sci, 21:571–582.
45. Moussa S H, Lawler J L, Young R. 2014. Genetic dissection of T4 lysis. J Bacteriol, 196:2201–2209.
46. Payne R J H, Jansen V A A. 2001. Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol, 208:37–48.
47. Payne R J H, Jansen V A A. 2003. Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet, 42:315–325.
48. Payne R J H, Phil D, Jansen V A A. 2000. Phage therapy: The peculiar kinetics of self-replicating pharmaceuticals. Clin Pharmacol Ther, 68:225–230.
49. Pratt J H. 1899. Secondary infection of the skin and subcutaneous tissues by the bacillus typhosus. J Boston Soc Med Sci, 3:170–173.
50. Ryan E M, Gorman S P, Donnelly R F, Gilmore B F. 2011. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharamcol, 63:1253–1264.
51. Sanders M E. 1987. Bacteriophages of industrial importance. In: Phage Ecology. Goyal S M, Gerba G P, Bitton G (eds). New York: John Wiley & Sons, pp211–244.
52. Slavcev R A, Hayes S. 2002. Rex-centric mutualism. J Bacteriol, 184:857–858.
53. Smith D L, Rooks D J, Fogg P C, Darby A C, Thomson N R, Mc-Carthy A J, Allison H E. 2012. Comparative genomics of Shiga toxin encoding bacteriophages. BMC Genomics, 13:311.
54. Stent G S. 1963. Molecular biology of bacterial viruses. San Francisco: WH Freeman and Co.
55. Sturino J M, Klaenhammer T R. 2006. Engineered bacteriophage-defence systems in bioprocessing. Nat Rev Microbiol, 4:395–404.
56. Tran T A, Struck D K, Young R. 2005. Periplasmic domains define holin-antiholin interactions in T4 lysis inhibition. J Bacteriol, 187:6631–6640.
57. Tran T A, Struck D K, Young R. 2007. The T4 RI antiholin has an N-terminal signal anchor release domain that targets it for degradation by DegP. J Bacteriol, 189:7618–7625.
58. Turner P E, Duffy S. 2008. Evolutionary ecology of multi-phage infections. In: Bacteriophage Ecology. Abedon ST (ed). Cambridge: Cambridge University Press, pp195–216.
59. Wei W, Krone S M. 2005. Spatial invasion by a mutant pathogen. J Theor Biol, 236:335–348.
60. Weinfeld H, Paigen K. 1964. Evidence for a new intermediate state of the viral chromosome during cooperative infection by host-modified lambda phage. Virology, 24:71–83.
61. Werner E R, Christensen J R. 1969. Infection by bacteriophage P1 and development of host-controlled restriction and modification and of lysogenic immunity. J Virol, 3:363–368.
62. Yamada T, Kawasaki T, Nagata S, Fujiwara A, Usami S, Fujie M. 2007. New bacteriophages that infect the phytopathogen Ralstonia solanacearum. Microbiology. 153:2630–2639.